Cholangitis screening: Difference between revisions
No edit summary |
|||
| Line 7: | Line 7: | ||
==Screening== | ==Screening== | ||
The cancer predominantly associated with cholangitis | The cancer predominantly associated with cholangitis is cholangiocarcinoma. There are no accepted screening programs for either disease. However, methods for detecting early onsets of cholangitis and cholangiocarcinoma include using [[biochemical markers]], scanning using [[positron emission tomography]] or [[MRI]] and endoscopic procedures such as endosonography and [[endoscopic retrograde cholangiopancreatography]].<ref name="pmid18508979">{{cite journal |vauthors=Kitiyakara T, Chapman RW |title=Chemoprevention and screening in primary sclerosing cholangitis |journal=Postgrad Med J |volume=84 |issue=991 |pages=228–37 |year=2008 |pmid=18508979 |doi=10.1136/pgmj.2007.064592 |url=}}</ref> | ||
==References== | ==References== | ||
Revision as of 19:47, 20 September 2016
|
Cholangitis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Cholangitis screening On the Web |
|
American Roentgen Ray Society Images of Cholangitis screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Farwa Haideri [2]
Overview
There are no accepted screening programs for cholangitis or cholangiocarcinoma, a cancer associated with this disease. Methods do exist to detect the early onset of both diseases, though.
Screening
The cancer predominantly associated with cholangitis is cholangiocarcinoma. There are no accepted screening programs for either disease. However, methods for detecting early onsets of cholangitis and cholangiocarcinoma include using biochemical markers, scanning using positron emission tomography or MRI and endoscopic procedures such as endosonography and endoscopic retrograde cholangiopancreatography.[1]
References
- ↑ Kitiyakara T, Chapman RW (2008). "Chemoprevention and screening in primary sclerosing cholangitis". Postgrad Med J. 84 (991): 228–37. doi:10.1136/pgmj.2007.064592. PMID 18508979.